Adam Rosenthal, Star Therapeutics founder and CEO

Stars align as ex-True North team nabs an­oth­er $90M to build out biotech con­stel­la­tion

Star Ther­a­peu­tics, which cre­at­ed two an­ti­body-fo­cused biotech star­tups with more in the works, has now reeled in a $90 mil­lion Se­ries C.

The round, dis­closed Tues­day morn­ing, brings the Bay Area biotech’s to­tal fi­nanc­ing to more than $190 mil­lion since it was found­ed in 2018. (It lat­er emerged from stealth in ear­ly 2022.)

Star’s biotech star­tups Ve­ga Ther­a­peu­tics and Elec­tra Ther­a­peu­tics fo­cus on treat­ing var­i­ous hema­to­log­i­cal and im­muno-on­col­o­gy in­di­ca­tions with an­ti­bod­ies cre­at­ed in-house.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.